Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.92 USD | +3.14% | -5.13% | -10.84% |
05-09 | UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating | MT |
05-08 | Transcript : REGENXBIO Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.84% | 761M | |
+4.61% | 109B | |
+11.83% | 105B | |
+0.84% | 22.25B | |
-11.74% | 22.09B | |
-7.61% | 18.68B | |
-38.36% | 17.58B | |
-9.81% | 16.85B | |
+4.93% | 13.76B | |
+37.44% | 12.46B |
- Stock Market
- Equities
- RGNX Stock
- News REGENXBIO Inc.
- Regenxbio Shares Jump Following Clinical Trial Results